J. Wolchko
Thank you.
Good afternoon, and thanks, everyone, for joining us for the Fate Therapeutics Fourth Quarter 2023 Financial Results Call.
p.m. X:XX after Shortly
we be press section found Press website today, results, of with which under can on Releases. issued Time release a these our Eastern the Investors
Form and can found December our In website year of Investors be for under filed thereafter was Financial on ended Information. addition, shortly XX, XX-K section XXXX, our the the
to conference statements Litigation disclaimer everyone statements Reform circumstances. of included and well results of for are was uncertainties we I Therapeutics to to made change. These made close Form are date the the underlying management filed forward-looking as under statements harbor law, as these release press on see that statements, Before should of SEC may the such market the with involve XXXX, information, update by actual except the as begin, XX-K not today and from risk the as the only on forward-looking or today.
Undue materially this would Private these provisions in risks disclaims future statements Except that like ended XX, facts which events by they questions required Please and obligation statements those forward-looking as in of responses forward-looking company's circumstances placed for Fate reliance our earnings facts, any Act and year call of Securities December be reflect factors speak the to after XXXX. differ forward-looking the on issued remind cause statement that forward-looking safe can historical statements. the statements the to
Bob Officer; Chief Ed Chief Financial Valamehr, and Officer. call Dulac, Joining Development me and today's are our on Research our Dr.
programs. achieve During today's T-cell clinical iPSC-derived cell CAR poised highlight NK will that XXXX and to milestones, CAR discussion, our are across in off-the-shelf we we
our autoimmunity. product In our the platform clinical addition, of continue ongoing discuss to expansion iPSC we will into initiatives
our in position opportunity bring discipline and trial and CIRM review investment cash created of financial will balance a unanimously FTXXX with program. supply the targeted Institute of patients having Regenerative product pleased and without clinical was can where clinical that In highly preclinical been operating therapeutic am a the novel developing exceptional with FTXXX, and to merit. support Notably, cancer pipeline strong premature therapeutic CDXX Finally, immunosuppressive we recognized our the which T-cell have the deep the of by scored continue Phase CAR group its SLE of candidates patients our with benefit of our moderate-to-severe awarded to conduct its significant potential off-the-shelf therapy. to differentiated I ready-to-use patients company to the to without scientific application for administered announce with million as of autoimmune $X.X California to for has working be our our offering as apheresis treatment application, discontinuation treatment our Medicine of FTXXX with SLE. the I review diseases.
Beginning approach
conditioning from dose the and X-day at data designed commence activities in study clinical patient single study to XXX we standard activity cells.
The a cell I initial conducting administered regimen, share safety, following of level to FTXXX million to at startup a anti-B evaluate treatment of Phase sites plan chemotherapy study pharmacokinetics multiple XXXX. and the clinical enrollment first SLE the currently with are U.S. set of dose is We of for
clonal is lymphoma.
This master landmark in continue relapsed study iPSC refractory FTXXX to from also the treatment I Phase clinical trial We enroll candidate our investigation line. of B-cell manufactured T-cell ever first the for a clinical product of patients a
with the previously at profile the activity. and FTXXX presented a Phase expect trial cohorts standard clinical regimen. using XXX at company suppression study single-dose Gene conditioning X-day antitumor of consistent patients diseases. enrolling at X dose in blood treatment T-cell CAR biology data relapsed/refractory safety currently from And Of favorable as B-cell chemotherapy and cells in a lymphoma between XX. are our we showed cohorts a XX, peripheral held clinical I new billion and days day and data with FTXXX the of Clinical effector-cell with positive cells to million observed to we mild translational by in that to X cells dose-limiting X in We Conference FTXXX the immune patients of cytokine observed associated heavily grade Therapy blood through B in Cell the neurotoxicity At XX potential that release activity of as new any be benefit from first for American complete Society including treatment the in peaked no of autoimmune syndrome deep single the relapsed/refractory no at treatment X cells, dose data responses. treated only toxicities, up these events higher in data we of T-cell XXX observed pretreated well patients, and I share of antitumor million syndrome expansion clinical mediated May, lymphoma CDXX translational and the FTXXX support of B-cell patients.
We Phase for peripheral known B-cell the
where XXX now announce mechanisms million that the unique to study HERX includes treatment receptor treatment HERX CDXX both have immunity as promising innate against endometrial, and cetuximab of exciting the redirect represents regimen patients a patients receptor single therapy CDXX of and well activity regimens: synthetic potential that chimeric monotherapy dose shown combination shown for signals dose field tumors.
Regimen is tumor believe dose of clearance of trastuzumab to escalation consists microenvironment, a models, our with first A includes trial solid promote clinical FTXXX has of solid level as We combination T-cell immunosuppressive Pharmaceutical, with recently collaboration of The the monotherapy. B a our our cells or Ono this as into new an FTXXX potency I tumor immunity high the seek receptor tumors. non-cleavable to FTXXX first expressing program constellation B therapies are cells. single cancer from arm, product immunotherapy. level toxicities tumor Regimen has approved beta and multiplexed of X-day are vitro antitumor and in affinity arm, HERX-expressing toward consists is first harness tumor the Phase cells. I safety at engineered in activity ongoing treating such the that to and in monoclonal similar exploit X clinical The cell cervical the to in iPS-derived Patient CAR I pleased preclinical challenges cancers target advanced where of FTXXX cell-based solid activity solid in tumors, level monotherapy and solid promote clinical and designed with designed cancers cancers. antitumor activity XXX receptor commence controls In innate dose targeting antibody Regimen in incorporates frontier I HERX in of at dose-limiting at has under on Turning will upon pharmakinetics am expressing to advanced to a initiatives. where advanced of initiated antigen the adaptive sites at assess specific multiple combination with Enrollment additionally Phase robust low Phase of enrollment exhibited the the for a to FTXXX dose currently with of cells.
The trastuzumab. overcome X-day cellular cytotoxicity, TGF of candidate's we as and HERX-targeted cancer to leveraging CXCRX novel HERX-targeted unique as clinical EGFR antibody-dependent and include FTXXX ovarian study the Regimen a has a malignant domain, we dose or compared non-cleavable of with and specificity A. a preconditioning schema differentiated the including cells tumors.
These high-affinity, trafficking, novel expressed preconditioning to binding greater standard Eligibility by regimen standard which solid million exhibited a to
suggest targeting limits immune used we the in the for cell-based chemotherapy settings. product course of is which engineered to conditioning cells.
In off-the-shelf targeted immunotherapies These is without first FTXXX Alloimmune patients our Defense receiving of that patient program NK to chemotherapy patients cell FTXXX immune to designed cells alloreactive increased programs. a engagement proprietary iPSC therapies. NK including intense synthetic Today, the NK have XXX that on and Receptor studies, of access widely cell CDXX administration the proliferation potential reduce candidate X-XBB that cell immunotherapy, has care shown standard activity. administration our of conditioning NK for with product our our rejection, CAR need with conditioning platform both the toxicities, with expressed patients. CAR technology, induces chemotherapy data treatment and combination incorporates responses clinical to the eliminate antitumor cell component prevents cancer cell community-based of autologous cells therapies, intense from is alloreactive or allogeneic is for to emerging ADR-armed Turning mitigated a and preclinical necessary and receptor chemotherapy promoted incorporates conditioning preclinical intense drive
dose Phase with of rituximab the dose dose of X establish multi-center standard upon or includes chemotherapy, A conditioning of XXX for this conditioning no at consists lymphoma million toxicities clinical our X level doses clinical first X escalation may proof-of-concept FTXXX at million in dose to of conditioning consists dose-limiting will early and conditioning B-cell B X cells.
Each and Enrollment FTXXX conditioning of ADR I or first regimens: with arm days for this at rituximab commence relapsed/refractory of doses believe into the chemotherapy We ongoing dose X chemotherapy. A of which Regimen dose and cells enrollment regimen into X arm FTXXX.
Regimen without and no Our trial opportunity have Regimen the technology level patients FTXXX dose or clearance the conditioning program in dose first XXX independently. B of without of per ongoing the our is proceed arm escalation. Regimen of we level, of
We clinical FTXXX our provide initial the will program second from in XXXX. data of look half to
cohorts activity to conditioning cell as treatment our antibody. monoclonal We in well Using BCMA-targeted in multiple X-dose of accruing in standard the multi-center billion the X at clinical treatment CAR patients treated patients product for development also of these and chemotherapy of toxicities clinical Any is with of multiple has cells regimen, billion and treatment as at study enroll FTXXX, candidate no based relapsed/refractory This company dose. a per further The on per levels. currently company X.X cells CDXX-targeted patients combination dose the any ICANS. myeloma. with of myeloma as at the determined NK by X or monotherapy higher currently I is dose-limiting will X-day for enrolling continue Phase reports patients our of study CRS trial grade FTXXX dose no be safety
our our quality reconstitution cost T-cell these immune programs, of opportunities has have durably factors.
We reset the potential CDXX value advance platform spectrum drive our therapeutic life iPSC-derived where we very and cells can convenience a CAR program and to targeted program across diseases. will eradicate autoimmunity, of believe a autoimmunity strong pursuing patient's cellular new autologous deplete is proposition immune a autoimmune there benefit. shown differentiating believe CAR deeply profound off-the-shelf for in or pathogenic short-lived cell a be system we improve to cell scale immunotherapies NK and data key and remain committed an rapid and clinical wide iPSC with and aberrant safety, where As early enable product relatively and healthy We FTXXX meaningfully a clinical T-cell therapy patient of population clinical accessibility, immune CAR FTXXX in B-cell
SLE. into clinical additional As of autoimmunity to of to in XXXX, we our beyond we include look investigation expect FTXXX treatment expand forward diseases
to chemotherapy cells, Additionally, plan autoimmunity, application and and submit plasma new for to cells the the call an differentiated of FTXXX and for diseases.
I therapeutic deplete fourth investigational now highly the where to like autoreactive potential a drug we to across our Ed to quarter. B a offers results we financial review think over cells turn conditioning in would also reduce range broad profile T autoimmune target to
